Please use this identifier to cite or link to this item:
https://doi.org/10.1016/j.acthis.2009.05.010
Title: | Molecular-assisted immunohistochemical optimization |
Authors: | Mohd, Omar M.F. Salto-Tellez, M. Huang, N. Ou, K. Jikuya, H. Ichikawa, T. Tan, P. Ou, K. Yu, K. Putti, T.C. Nishimura, O. |
Keywords: | Antibody optimization Immunohistochemistry validation Molecular biology Molecular diagnostics Protein immunolocalization |
Issue Date: | 2010 |
Citation: | Mohd, Omar M.F., Salto-Tellez, M., Huang, N., Ou, K., Jikuya, H., Ichikawa, T., Tan, P., Ou, K., Yu, K., Putti, T.C., Nishimura, O. (2010). Molecular-assisted immunohistochemical optimization. Acta Histochemica 112 (6) : 519-528. ScholarBank@NUS Repository. https://doi.org/10.1016/j.acthis.2009.05.010 |
Abstract: | Immunohistochemistry (IHC) is an essential tool in diagnostic surgical pathology, allowing analysis of protein subcellular localization. The use of IHC by different laboratories has lead to inconsistencies in published literature for several antibodies, due to either interpretative (inter-observer variation) or technical reasons. These disparities have major implications in both clinical and research settings. In this study, we report our experience conducting an IHC optimization of antibodies against five proteins previously identified by proteomic analysis to be breast cancer biomarkers, namely 6PGL (PGLS), CAZ2 (CAPZA2), PA2G4 (EBP1) PSD2 and TKT. Large variations in the immunolocalizations and intensities were observed when manipulating the antigen retrieval method and primary antibody incubation concentration. However, the use of an independent molecular analysis method provided a clear indication in choosing the appropriate biologically and functionally relevant "staining pattern". Without this latter step, each of these contradictory results would have been a priori "technically acceptable" and would have led to different biological and functional interpretations of these proteins and potentially different applications in a routine pathology setting. Thus, we conclude that full validation of immunohistochemical protocols for scientific and clinical use will require the incorporation of biological knowledge of the biomarker and the disease in question. © 2009 Elsevier GmbH. All rights reserved. |
Source Title: | Acta Histochemica |
URI: | http://scholarbank.nus.edu.sg/handle/10635/33169 |
ISSN: | 00651281 16180372 |
DOI: | 10.1016/j.acthis.2009.05.010 |
Appears in Collections: | Staff Publications |
Show full item record
Files in This Item:
There are no files associated with this item.
SCOPUSTM
Citations
4
checked on Feb 14, 2019
WEB OF SCIENCETM
Citations
4
checked on Feb 5, 2019
Page view(s)
159
checked on Dec 29, 2018
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.